Evidence map›Paper›PMID 33479121›Full record

ArticleScience (New York, N.Y.)2021

Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.

Jeffrey J Quinn, Matthew G Jones, Ross A Okimoto, Shigeki Nanjo, Michelle M Chan, Nir Yosef, Trever G Bivona, Jonathan S Weissman

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

189 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jeffrey J Quinn *Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-6497-1605
Matthew G Jones *Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-0363-4493
Ross A OkimotoUCSF Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-4467-8476
Shigeki NanjoUCSF Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-8356-9849
Michelle M ChanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-9451-9716
Nir YosefCenter for Computational Biology, University of California, Berkeley, Berkeley, CA, USA. weissman@wi.mit.edu trever.bivona@ucsf.edu niryosef@berkeley.edu.ORCID https://orcid.org/0000-0001-9004-1225
Trever G BivonaDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. weissman@wi.mit.edu trever.bivona@ucsf.edu niryosef@berkeley.edu.ORCID https://orcid.org/0000-0001-5734-4128
Jonathan S WeissmanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA. weissman@wi.mit.edu trever.bivona@ucsf.edu niryosef@berkeley.edu.ORCID https://orcid.org/0000-0003-2445-670X

Funding

Systems Biological Analysis of Innate and Adaptive Responses to VaccinationU19AI090023 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, LI, SHUZHAO · 2010 to 2021
$45.0M
Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7M
UCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9M
BMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6M
Characterization of YAP as a rational companion target in lung cancerR01CA204302 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona · 2017 to 2026
$3.7M
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer TreatmentR01CA169338 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2013 to 2023
$3.4M
Harnessing CRISPR for Targeted and Inducible Epigenomic ReprogrammingR01DA036858 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A, QI, LEI STANLEY · 2013 to 2017
$2.9M
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granulesR01CA231300 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G, HUANG, BO · 2019 to 2023
$2.3M
Optimizing biologically-based rational polytherapy in ALK+ lung cancerR01CA211052 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIVONA, TREVER G · 2017 to 2021
$1.8M
Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasisK08CA222625 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKIMOTO, ROSS · 2018 to 2022
$887k
Profiling chromatin-associated long noncoding RNAs in numerous biological contextsF32GM125247 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI QUINN, JEFFREY JEROME · 2017 to 2019
$179k
Howard Hughes Medical InstituteNCI NIH HHS K08 CA222625NCI NIH HHS R01 CA169338NCI NIH HHS R01 CA204302NCI NIH HHS R01 CA211052NCI NIH HHS R01 CA231300NCI NIH HHS U54 CA224081NHGRI NIH HHS RM1 HG009490NIAID NIH HHS U19 AI090023NIDA NIH HHS R01 DA036858NIGMS NIH HHS F32 GM125247NIGMS NIH HHS T32 GM067547
6 · The paper itself

Abstract

Detailed phylogenies of tumor populations can recount the history and chronology of critical events during cancer progression, such as metastatic dissemination. We applied a Cas9-based, single-cell lineage tracer to study the rates, routes, and drivers of metastasis in a lung cancer xenograft mouse model. We report deeply resolved phylogenies for tens of thousands of cancer cells traced over months of growth and dissemination. This revealed stark heterogeneity in metastatic capacity, arising from preexisting and heritable differences in gene expression. We demonstrate that these identified genes can drive invasiveness and uncovered an unanticipated suppressive role for

Indexed as

Neoplasm MetastasisAnimalsCell LineageCell Line, TumorClone CellsCRISPR-Cas SystemsGene Expression Regulation, NeoplasticHumansKeratin-17Lung NeoplasmsMiceNeoplasm InvasivenessNeoplasm SeedingNeoplasm TransplantationPhenotypeRNA-SeqKeratin-17KRT17 protein, human

Identifiers

PMID33479121
PMCPMC7983364

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.